From Left to Right: Eiry Roberts (Chief Medical Officer), Jude Onyia (Chief Scientific Officer), Ingrid Delaet (Chief Regulatory Officer), Kyle Gano (Chief Business Development and Strategy Officer)

Table of Contents

  1. CEO Letter
  2. About Neurocrine Biosciences

6 Our Approach to Sustainability

8 Patients and Products

13 Our People

  1. Our Communities
  2. Our Environment

24 Integrity

27 Appendix

Letter from our CEO

Kevin C. Gorman, Ph.D.

Chief Executive Officer

For over 30 years, Neurocrine Biosciences has been focused on advancing therapies that address complex neurological, neuroendocrinological, and neuropsychiatric conditions. As one of the company's co-founders, we have established a culture rooted in doing the right thing for our patients, our people, and the communities where we work and live.

With a growing commercial product in INGREZZA for the treatment of tardive dyskinesia and the deepest, most diversified pipeline we have ever had in our company's history, we continue to make steady progress on our mission to be the leading neuroscience focused company. When you look across all of our programs, odds are very likely that you have a family member or a friend who suffer from a condition that Neurocrine is focused on: Major Depressive Disorder, Schizophrenia, and Epilepsy among others.

This year, we reviewed our 2023 corporate goals with the entire Neurocrine staff to ensure environmental, social and governance issues are featured in our annual goals. Neurocrine's 2023 Corporate Sustainability Report offers insight into how we are addressing our most important sustainability impacts. Recent achievements and priorities described in this report include:

  • An Exposé Featuring our Head of Diversity, Equity and Inclusion (DE&I) Programs
  • Supply Chain Risk Assessment and Risk Mitigation Efforts
  • Ensuring Product Quality
  • Reducing our Environmental Impact at our New Corporate Campus

Neurocrine is a company that continues to evolve. Over the next several years, you are going to see Neurocrine advance programs that are going to fundamentally change lives. You are going to see us advance programs that are truly disease modifying or even curative. I hope you find this year's report to be an insightful window into many of the good things we are doing on our evolutionary journey.


3 Neurocrine Biosciences 2023 Corporate Sustainability Report

< Return to ToC >

About Neurocrine Biosciences

Neurocrine Biosciences is a leading neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs, but few options.

We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine, and neuropsychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, Parkinson's disease, endometriosis* and uterine fibroids*, as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit neurocrine.com, and follow the company on LinkedIn, Twitterand Facebook.

*in collaboration with AbbVie


2022 revenue


Total employees

5 phase 3



Programs in Clinical Development

4 Neurocrine Biosciences 2023 Corporate Sustainability Report

< Return to ToC >



We are driven and love what we do. We are committed to our goals and to making a difference.


We do the right thing for patients and our community. We take accountability. We speak up.


We trust one another.

We are inclusive. We are respectful. We are transparent. Together we succeed.


We seek and create optimal solutions.


We do not quit. We adapt.

We accomplish what others cannot.

5 Neurocrine Biosciences 2023 Corporate Sustainability Report

< Return to ToC >


  • Original Link
  • Original Document
  • Permalink


Neurocrine Biosciences Inc. published this content on 06 June 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 06 June 2023 16:18:06 UTC.